26 Jul Albumedix
Phil Morton, Ph.D., Chief Technology Officer
Oct. 12 | 3:15pm | Oxford Biomedica Ballroom
Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics globally. The company’s solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services, and drug-enhancing technologies (Veltis®). Recombumin® albumins have been used throughout the entire cell therapy development process, including improving culture, expansion, cell isolation, formulation, and cryopreservation. The effect is incredibly pronounced in high stress environments such as freeze and thaw as well as improving viral vector stability. By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.